Tara Gomes

PhD, MHSc

Scientist

Biography

Tara Gomes is an epidemiologist and Principal Investigator of the Ontario Drug Policy Research Network (ODPRN), a provincial network of researchers with expertise in pharmaceutical utilization, outcomes and policy who rapidly conduct research for drug decision-makers in Ontario and across Canada.  She holds a Canada Research Chair in Drug Policy Research and Evaluation, is a Scientist in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital and ICES, and is an assistant professor at the University of Toronto.  Her research is focused on pharmacoepidemiology, drug safety and drug policy research leveraging large, administrative databases, and she has published over 200 peer-reviewed articles and over 100 policy reports in this area.  Dr. Gomes also works closely with government regulators at the provincial and national level to develop evidence to inform policies related to opioid use disorder and opioid-related harm through the Ontario Opioid Drug Observatory.  In 2014, she was awarded the Institute for Public Administration of Canada’s Bronze Public Sector Leadership Award in Health and Education to recognize the impact of the ODPRN’s work.

Recent Publications

  1. Ledlie, S, Gomes, T, Dolovich, L, Bailey, C, Lallani, S, Frigault, DS et al.. Medication errors in community pharmacies: Evaluation of a standardized safety program. Explor Res Clin Soc Pharm. 2023;9 :100218. doi: 10.1016/j.rcsop.2022.100218. PubMed PMID:36632372 PubMed Central PMC9827048.
  2. Antoniou, T, McCormack, D, Kitchen, S, Pajer, K, Gardner, W, Lunsky, Y et al.. Geographic variation and sociodemographic correlates of prescription psychotropic drug use among children and youth in Ontario, Canada: a population-based study. BMC Public Health. 2023;23 (1):85. doi: 10.1186/s12889-022-14677-6. PubMed PMID:36631810 PubMed Central PMC9832754.
  3. Kurteva, S, Abrahamowicz, M, Weir, D, Gomes, T, Tamblyn, R. Determinants of long-term opioid use in hospitalized patients. PLoS One. 2022;17 (12):e0278992. doi: 10.1371/journal.pone.0278992. PubMed PMID:36520865 PubMed Central PMC9754198.
  4. Gomes, T, Men, S, Campbell, TJ, Tadrous, M, Mamdani, MM, Paterson, JM et al.. Changing patterns of opioid initiation for pain management in Ontario, Canada: A population-based cross-sectional study. PLoS One. 2022;17 (12):e0278508. doi: 10.1371/journal.pone.0278508. PubMed PMID:36480526 PubMed Central PMC9731435.
  5. Konstantelos, N, Tourchian, N, McCormack, D, Lecce, P, Tadrous, M, Gomes, T et al.. Impact of policy changes and drug shortages on acamprosate and naltrexone use in Ontario, Canada. Drug Alcohol Depend. 2023;242 :109705. doi: 10.1016/j.drugalcdep.2022.109705. PubMed PMID:36463765 .
  6. Ladha, KS, Kitchen, S, Miles, S, Clarke, H, Gomes, T. Use of injections for chronic pain from 2010 to 2019 in Ontario, Canada. Can J Anaesth. 2022; :. doi: 10.1007/s12630-022-02357-3. PubMed PMID:36450946 .
  7. Guan, Q, Men, S, Lunsky, Y, Juurlink, DN, Bronskill, SE, Wunsch, H et al.. New opioid use and risk of opioid-related adverse events among adults with intellectual and developmental disabilities in Ontario, Canada. BJPsych Open. 2022;8 (6):e208. doi: 10.1192/bjo.2022.612. PubMed PMID:36440532 PubMed Central PMC9707500.
  8. Paul, LA, Bayoumi, AM, Chen, C, Kocovska, E, Smith, BT, Raboud, JM et al.. Evaluation of the gap in delivery of opioid agonist therapy among individuals with opioid-related health problems: a population-based retrospective cohort study. Addiction. 2022; :. doi: 10.1111/add.16096. PubMed PMID:36401610 .
  9. Chang, A, Chaudhry, S, McCormack, D, Gomes, T, Shivji, A, Tadrous, M et al.. Impact of the COVID-19 Controlled Drugs and Substances Act exemption on pharmacist prescribing of opioids, benzodiazepines and stimulants in Ontario: A cross-sectional time-series analysis. Can Pharm J (Ott). 2022;155 (6):326-333. doi: 10.1177/17151635221126481. PubMed PMID:36386607 PubMed Central PMC9647400.
  10. Ho, M, Tadrous, M, Iacono, A, Suda, K, Gomes, T. Outpatient purchasing patterns of hydroxychloroquine and ivermectin in the USA and Canada during the COVID-19 pandemic: an interrupted time series analysis from 2016 to 2021. J Antimicrob Chemother. 2022;78 (1):242-251. doi: 10.1093/jac/dkac382. PubMed PMID:36374569 .
Search PubMed

Affiliations & Other Activities

  • Assistant Professor, Leslie Dan Faculty of Pharmacy, University of Toronto
  • Assistant Professor, Institute for Health Policy, Management and Evaluation, University of Toronto
  • Scientist, Institute for Clinical Evaluative Sciences
  • Principal Investigator, Ontario Drug Policy Research Network